Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07145112 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 20 → 25 participants
    • Primary completion moved earlier from Jul 2027 to Mar 2027
    • Study completion moved earlier from Dec 2027 to Sep 2027
    • Eligibility criteria expanded, about 35 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 20, 2025 to Oct 1, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.
Trial Details
NCT Number NCT07145112
Lead Sponsor University of California, Davis
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Glioblastoma
Related terms Glioblastoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov